Protaras

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, November 3, 2023

The Company remains on track to report preliminary results in the first half of 2024.

Key Points: 
  • The Company remains on track to report preliminary results in the first half of 2024.
  • General and administrative expenses for both the third quarter of 2023 and 2022 were $4.5 million.
  • For the third quarter of 2023, Protara reported a net loss of $9.9 million, or $0.87 per share, compared with a net loss of $7.7 million, or $0.68 per share, for the same period in 2022.
  • Net loss for the third quarter of 2023 included approximately $1.4 million of stock-based compensation expenses.

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, August 3, 2023

Research and development expenses for the second quarter of 2023 increased to $7.2 million from $3.1 million during the second quarter of 2022, primarily reflecting an increase in expenses related to clinical and non-clinical trial activities for TARA-002.

Key Points: 
  • Research and development expenses for the second quarter of 2023 increased to $7.2 million from $3.1 million during the second quarter of 2022, primarily reflecting an increase in expenses related to clinical and non-clinical trial activities for TARA-002.
  • General and administrative expenses for the second quarter of 2023 decreased to $4.9 million from $5.6 million for the prior year period, primarily due to lower employee related expenses.
  • For the second quarter of 2023, Protara reported a net loss of $11.3 million, or $1.00 per share, compared with a net loss of $8.5 million, or $0.76 per share, for the same period in 2022.
  • Net loss for the second quarter of 2023 included approximately $1.6 million of stock-based compensation expenses.

Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, May 4, 2023

Protara’s prospective study to enhance understanding of the incidence of IFALD in patients dependent on parenteral nutrition is ongoing, with results expected in the third quarter of 2023.

Key Points: 
  • Protara’s prospective study to enhance understanding of the incidence of IFALD in patients dependent on parenteral nutrition is ongoing, with results expected in the third quarter of 2023.
  • Research and development (R&D) expenses for the first quarter of 2023 decreased to $5.1 million from $5.3 million during the first quarter of 2022.
  • For the first quarter of 2023, Protara reported a net loss of $9.0 million, or $0.80 per share, compared with a net loss of $10.8 million, or $0.96 per share, for the same period in 2022.
  • Net loss for the first quarter of 2023 included approximately $1.6 million of stock-based compensation expenses.

Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12 through September 14, 2022.

Key Points: 
  • NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12 through September 14, 2022.
  • The prerecorded presentation will become available on-demand on Monday, September 12, 2022 at 7:00 a.m.
  • ET and can be accessed by visiting the Events and Presentations section of the Companys website: https://ir.protaratx.com.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases.

Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 17, 2022

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright Global Investment Conference being held May 23 through May 26, 2022.

Key Points: 
  • NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright Global Investment Conference being held May 23 through May 26, 2022.
  • The prerecorded presentation will become available on Tuesday, May 24, 2022 at 7:00 a.m.
  • ET and can be accessed by visiting the Events and Presentations section of the Companys website: https://ir.protaratx.com .
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Protara Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, March 2, 2022

The webcasts will be archived on the Companys website for 90 days following the presentations.

Key Points: 
  • The webcasts will be archived on the Companys website for 90 days following the presentations.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
  • Protaras portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
  • For more information, visit www.protaratx.com .

Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference

Retrieved on: 
Tuesday, February 1, 2022

NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference onFebruary 9, 2022at4:00 PM ET.

Key Points: 
  • NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference onFebruary 9, 2022at4:00 PM ET.
  • A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Companys website: https://ir.protaratx.com.
  • The webcast will be archived on the Companys website for 90 days following the presentation.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
Tuesday, January 4, 2022

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.

Key Points: 
  • NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.
  • The prerecorded presentation will become available on Monday, January 10, 2022 at 7:00am ET and can be accessed by visiting the Events and Presentations section of the Companys website: https://ir.protaratx.com .
  • The webcast will be archived on the Companys website for 90 days following the presentation.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, October 25, 2021

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protaras new General Counsel.

Key Points: 
  • NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protaras new General Counsel.
  • The Compensation Committee of Protaras Board of Directors approved the awards as an inducement material to Ms. Grendells employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
  • For more information, visit www.protaratx.com

Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Retrieved on: 
Friday, September 17, 2021

NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held in a virtual setting on Wednesday, September 22, 2021 at 12:25pm ET.

Key Points: 
  • NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held in a virtual setting on Wednesday, September 22, 2021 at 12:25pm ET.
  • A webcast of the presentation can be accessed by visiting the Events and Presentations section of the Companys website: https://ir.protaratx.com.
  • The webcast will be archived on the Companys website for 90 days following the presentation.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.